» Articles » PMID: 28636670

Identification of Novel Small Molecules That Inhibit STAT3-dependent Transcription and Function

Overview
Journal PLoS One
Date 2017 Jun 22
PMID 28636670
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Activation of Signal Transducer and Activator of Transcription 3 (STAT3) has been linked to several processes that are critical for oncogenic transformation, cancer progression, cancer cell proliferation, survival, drug resistance and metastasis. Inhibition of STAT3 signaling has shown a striking ability to inhibit cancer cell growth and therefore, STAT3 has become a promising target for anti-cancer drug development. The aim of this study was to identify novel inhibitors of STAT-dependent gene transcription. A cellular reporter-based system for monitoring STAT3 transcriptional activity was developed which was suitable for high-throughput screening (Z' = 0,8). This system was used to screen a library of 28,000 compounds (the ENAMINE Drug-Like Diversity Set). Following counter-screenings and toxicity studies, we identified four hit compounds that were subjected to detailed biological characterization. Of the four hits, KI16 stood out as the most promising compound, inhibiting STAT3 phosphorylation and transcriptional activity in response to IL6 stimulation. In silico docking studies showed that KI16 had favorable interactions with the STAT3 SH2 domain, however, no inhibitory activity could be observed in the STAT3 fluorescence polarization assay. KI16 inhibited cell viability preferentially in STAT3-dependent cell lines. Taken together, using a targeted, cell-based approach, novel inhibitors of STAT-driven transcriptional activity were discovered which are interesting leads to pursue further for the development of anti-cancer therapeutic agents.

Citing Articles

Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer.

Fu H, Han X, Guo W, Zhao X, Yu C, Zhao W Sci Rep. 2024; 14(1):22988.

PMID: 39362925 PMC: 11449925. DOI: 10.1038/s41598-024-71962-7.


approaches for drug repurposing in oncology: a scoping review.

Cavalcante B, Freitas R, Siquara da Rocha L, Santos R, Souza B, Ramos P Front Pharmacol. 2024; 15:1400029.

PMID: 38919258 PMC: 11196849. DOI: 10.3389/fphar.2024.1400029.


Recent advances in lycopene and germacrene a biosynthesis and their role as antineoplastic drugs.

Fordjour E, Liu C, Yang Y, Bai Z World J Microbiol Biotechnol. 2024; 40(8):254.

PMID: 38916754 DOI: 10.1007/s11274-024-04057-0.


Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers.

Ni Y, Low J, Silke J, OReilly L Front Immunol. 2022; 13:835997.

PMID: 35844493 PMC: 9277720. DOI: 10.3389/fimmu.2022.835997.


Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem.

Smigiel J, Taylor S, Bryson B, Tamagno I, Polak K, Jackson M J Cancer Metastasis Treat. 2020; 5.

PMID: 32355893 PMC: 7192216. DOI: 10.20517/2394-4722.2019.26.


References
1.
Zhang X, Yue P, Page B, Li T, Zhao W, Namanja A . Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A. 2012; 109(24):9623-8. PMC: 3386073. DOI: 10.1073/pnas.1121606109. View

2.
Friesner R, Murphy R, Repasky M, Frye L, Greenwood J, Halgren T . Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006; 49(21):6177-96. DOI: 10.1021/jm051256o. View

3.
Baell J, Holloway G . New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. DOI: 10.1021/jm901137j. View

4.
Ramsauer K, Farlik M, Zupkovitz G, Seiser C, Kroger A, Hauser H . Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 gene. Proc Natl Acad Sci U S A. 2007; 104(8):2849-54. PMC: 1815270. DOI: 10.1073/pnas.0610944104. View

5.
Giri D, Ozen M, Ittmann M . Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001; 159(6):2159-65. PMC: 1850613. DOI: 10.1016/S0002-9440(10)63067-2. View